How should nail pitting in a child be evaluated and managed?

Nail Pitting in a Child: Evaluation and Management

Nail pitting in a child should prompt immediate evaluation for psoriasis and alopecia areata as the two most common causes, with psoriasis being particularly important to identify given its implications for systemic disease and quality of life.

Primary Differential Diagnosis

Nail pitting in children has a focused differential diagnosis:

• Psoriasis: The most clinically significant cause requiring systemic evaluation
• Alopecia areata: Present in 46% of children with alopecia areata, with nail pitting detected in 92 patients in one large series 1
• Less common: Trachyonychia, eczema, or isolated nail dystrophy 2

Initial Evaluation Approach

Look for these specific clinical features:

• Skin examination: Check for erythematous scaly plaques on extensor surfaces, scalp involvement, inverse areas, and palmoplantar disease
• Scalp and hair: Assess for patchy hair loss patterns characteristic of alopecia areata
• Joint examination: Evaluate for joint swelling, tenderness, or dactylitis (psoriatic arthritis risk)
• Nail characteristics: Document the pattern (isolated pitting vs. other changes like onycholysis, oil spots, subungual hyperkeratosis)
• Family history: Psoriasis or autoimmune conditions

Critical clinical pearl: Nail involvement in pediatric psoriasis indicates increased risk for both overall disease severity and development of psoriatic arthritis 3. This makes identification crucial for long-term outcomes.

Management Algorithm

If Psoriasis is Confirmed:

For isolated or mild nail psoriasis:

• Start with topical tazarotene 0.05% gel applied daily to affected nails, though local irritation is common 4
• Consider combination with topical corticosteroids to minimize irritation
• Counsel adolescent females about teratogenicity

For severe nail disease or systemic psoriasis:

• Biologic therapies have been used off-label for severe nail disease with anecdotal effectiveness 4
• Etanercept (FDA-approved for ages ≥4 years): 0.8 mg/kg/week (max 50 mg/week) showed 57% PASI 75 achievement in children 4
• Ustekinumab (FDA-approved for ages ≥12 years)
• Adalimumab (approved in Europe for ages ≥4 years): 0.8 mg/kg every other week achieved 58% PASI 75 4

If Alopecia Areata is Confirmed:

• Nail changes may precede, follow, or occur as isolated findings 5
• Observation is often appropriate, especially in children where spontaneous improvement is possible 5
• Treatment is not always necessary unless cosmetically disfiguring or functionally impairing
• Consider dermatology referral for severe cases or when associated with alopecia totalis/universalis (37 of 92 patients with nail pitting had these severe forms) 1

Common Pitfalls to Avoid

1. Missing psoriatic arthritis risk: Nail involvement signals higher risk for joint disease—always examine joints 3
2. Overlooking quality of life impact: Even asymptomatic nail changes can be cosmetically disfiguring and reduce quality of life 5
3. Premature treatment in alopecia areata: Unlike psoriasis, nail changes in alopecia areata often improve spontaneously, particularly in children 5
4. Inadequate vaccination status: Before initiating biologics, ensure patients are current on vaccinations 4

When to Refer

• Severe or extensive nail involvement
• Suspected psoriatic arthritis
• Failed topical therapy requiring systemic treatment
• Diagnostic uncertainty requiring nail biopsy 5
• Cosmetically disfiguring changes affecting quality of life